ZYTIGA, the prostate cancer treatment drug developed by specialist healthcare company BTG, has been approved by the European Medicines Agency (EMA), the firm announced on Tuesday morning.
BTG, which develops and commercialises pharmaceutical products, highlighted the announcement by pharmaceuticals group Janssen-Cilag International that the Committee for Medial Products for Human Use (CHMP) of the EMA has "granted a positive opinion recommending approval" of ZYTIGA.
ZYTIGA, otherwise known as abiraterone acetate, is the oral, once-daily medication for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"If endorsed by the European Commission, the recommendation would expand the indication for ZYTIGA, which is currently approved for use in combination withprednisone/prednisolone to treat men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy regimen."
Janssen expects to receive the regulatory decision from the European Commission in early 2013.
"This positive opinion brings us a step closer to being able to offer ZYTIGA to advanced cancer patients earlier in the course of their disease and fills a previously unmet medical need," said Jane Griffiths, the Chairman of Janssen's Middle-East and African division.
"If approved, the expanded indication will provide a welcome new option for patients with castration-resistant prostate cancer. It could not only give men a chance of extended survival, but may also delay the need for chemotherapy and help to improve their quality of life."
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the USMedium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.
